Maarten Jacubos Postma

Maarten Jacubos Postma's AcademicInfluence.com Rankings

Medical

#1940

World Rank

#2328

Historical Rank

Public Health

#269

World Rank

#278

Historical Rank

Epidemiology

#316

World Rank

#333

Historical Rank

medical Degrees

Download Badge

Medical

Maarten Jacubos Postma's Degrees

PhD Epidemiology University of Washington
Masters Public Health University of Washington
Bachelors Biomedical Sciences University of Amsterdam

Why Is Maarten Jacubos Postma Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Maarten Jacubos Postma's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (5789)
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (3330)
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (2141)
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (1515)
Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2019) (1485)
Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2018) (1481)
Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2018) (1121)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 (2019) (1041)
Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2018) (934)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 (2018) (899)
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 (2021) (822)
Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2020) (627)
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (495)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. (2019) (336)
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 (2021) (331)
Five insights from the Global Burden of Disease Study 2019 (2020) (291)
Global Burden of Multiple Myeloma (2018) (241)
Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017 (2019) (233)
Need for differential discounting of costs and health effects in cost effectiveness analyses (2005) (221)
Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. (2010) (218)
Sodium intake, ACE inhibition, and progression to ESRD. (2012) (218)
Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5 (2012) (199)
Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2018) (186)
Reducing the costs of chronic kidney disease while delivering quality health care: a call to action (2017) (186)
Clinical and economic impact of non-adherence in COPD: a systematic review. (2014) (181)
Discounting in economic evaluations: stepping forward towards optimal decision rules. (2007) (163)
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. (2009) (143)
Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. (2001) (129)
Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines (2010) (125)
Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case (2013) (122)
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention tr (2006) (112)
The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges (2013) (108)
Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019 (2021) (108)
Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study. (2011) (103)
Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. (2015) (97)
Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature (2016) (96)
Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community (2015) (95)
The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis (2013) (94)
A report on the status of vaccination in Europe. (2018) (92)
The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship (2017) (90)
Primary Prevention of Major Cardiovascular and Cerebrovascular Events with Statins in Diabetic Patients (2012) (87)
Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes (2012) (86)
Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy (2020) (83)
Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands (2016) (82)
Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017 (2020) (79)
Universal HIV screening of pregnant women in England: cost effectiveness analysis (1999) (71)
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. (2014) (71)
Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens (2001) (71)
Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017 (2020) (71)
Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. (2003) (71)
The global distribution of lymphatic filariasis, 2000–18: a geospatial analysis (2020) (70)
Dynamic Transmission Modeling (2012) (70)
Costs and Effects of Chlamydial Screening: Dynamic versus Static Modeling (2005) (70)
Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. (2010) (68)
Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: a cost-effectiveness analysis (2014) (68)
Diagnostic accuracy of culture-based and PCR-based detection tests for methicillin-resistant Staphylococcus aureus: a meta-analysis. (2011) (66)
Cost-Benefit Analysis of the Detection of Prescribing Errors by Hospital Pharmacy Staff (2002) (66)
Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1 (2021) (64)
Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data. (2006) (62)
Cost–effectiveness of varicella vaccination programs: an update of the literature (2008) (61)
Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3 (2020) (60)
Effect of vaccination programmes on mortality burden among children and young adults in the Netherlands during the 20th century: a historical analysis. (2016) (60)
Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. (2014) (59)
Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. (2004) (58)
Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. (2011) (58)
Financial evaluations of antibiotic stewardship programs—a systematic review (2015) (58)
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. (2014) (56)
Direct Medical Costs of Serious Gastrointestinal Ulcers among Users of NSAIDs (2007) (56)
Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatis in a high-risk health centre population in Amsterdam using mailed home-collected urine samples (2004) (54)
Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States (2003) (54)
Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model (2010) (53)
Cost-effectiveness of vaccination against meningococcal B among Dutch infants (2013) (52)
Modelling the Costs and Effects of Selective and Universal Hospital Admission Screening for Methicillin-Resistant Staphylococcus aureus (2011) (52)
Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. (2010) (52)
Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17 (2020) (52)
Persistence with osteoporosis medication among newly-treated osteoporotic patients (2013) (50)
Burden of early, advanced and metastatic breast cancer in The Netherlands (2018) (49)
Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. (2004) (49)
Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents (2012) (48)
Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model (2011) (47)
Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017 (2020) (47)
Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands. (2010) (47)
Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017 (2020) (47)
Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis. (2010) (46)
Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050 (2021) (46)
Cost Considerations in the Treatment of Colorectal Cancer (2012) (46)
A systematic review of the health economic consequences of quadrivalent influenza vaccination (2017) (46)
Impact of pharmacist recommendations on the cost of drug therapy in icu patients at a Malaysian hospital (2003) (45)
Adherence to hypertension medication: Quantitative and qualitative investigations in a rural Northern Vietnamese community (2017) (45)
Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world (2011) (45)
COPD in the Working Age Population: The Economic Impact on Both Patients and Government (2013) (45)
Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis (2014) (44)
Mapping child growth failure across low- and middle-income countries (2020) (44)
Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs (2017) (43)
Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. (2007) (43)
Cancer incidence and mortality in Serbia 1999–2009 (2013) (43)
Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019 (2021) (42)
Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy (2004) (42)
A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs (2018) (42)
Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands (2012) (42)
Pharmacoeconomics of Influenza Vaccination in the Elderly (2000) (41)
Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments (2015) (41)
Retrospective public health impact of a quadrivalent influenza vaccine in the United States (2015) (40)
The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment. (2009) (40)
Economic Burden in Chinese Patients with Diabetes Mellitus Using Electronic Insurance Claims Data (2016) (39)
Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. (2013) (39)
Measuring the impact of antimicrobial stewardship programs (2016) (39)
Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review. (2014) (38)
Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis (2012) (38)
Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe (2017) (38)
Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. (2001) (37)
BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands (2009) (37)
Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination (2011) (37)
Health-related quality of life in Indonesian type 2 diabetes mellitus outpatients measured with the Bahasa version of EQ-5D (2019) (37)
Cost effectiveness of expanded antenatal HIV testing in London (2000) (37)
The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt (2012) (36)
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019 (2021) (36)
Prevention of Surgical Site Infections: A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics (2018) (36)
Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men (2013) (36)
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. (2010) (36)
Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands (2014) (35)
A multicentre study of patient survival, disability, quality of life and cost of care (2004) (35)
Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. (2011) (35)
Health economics of blood transfusion safety--focus on sub-Saharan Africa. (2010) (35)
Review of tick-borne encephalitis and vaccines: clinical and economical aspects (2015) (35)
Economic evaluation of influenza vaccination. Assessment for The Netherlands. (1999) (35)
Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands. (2012) (35)
Economic evaluations of rotavirus immunization for developing countries: a review of the literature (2011) (34)
Impact of Rotavirus Vaccination on Hospitalisations in Belgium: Comparing Model Predictions with Observed Data (2013) (34)
Translation, Revision, and Validation of the Diabetes Distress Scale for Indonesian Type 2 Diabetic Outpatients with Various Types of Complications. (2017) (34)
Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. (2011) (34)
Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. (2009) (34)
Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). (2010) (34)
A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus (2013) (34)
Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study. (2020) (33)
Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands (2013) (33)
Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature (2010) (33)
The Fiscal Consequences Attributed to Changes in Morbidity and Mortality Linked to Investments in Health Care: A Government Perspective Analytic Framework. (2017) (33)
Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands (2013) (33)
The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review (2018) (32)
Hepatitis C and injecting drug use: impact, costs and policy options. (2004) (32)
Economic evaluation of folic acid food fortification in The Netherlands. (2008) (32)
Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries. (2012) (32)
Gaps in COPD Guidelines of Low- and Middle-Income Countries (2020) (32)
Evolution of the health economics of cervical cancer vaccination. (2008) (31)
Evaluating interventions to improve somatic health in severe mental illness: a systematic review (2013) (31)
Towards a healthier discount procedure (2005) (31)
Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis. (2001) (30)
Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam (2016) (30)
Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model (2016) (30)
HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. (2008) (30)
Mapping disparities in education across low- and middle-income countries (2019) (30)
Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. (2014) (29)
Cost-Minimization Model of a Multidisciplinary Antibiotic Stewardship Team Based on a Successful Implementation on a Urology Ward of an Academic Hospital (2015) (29)
Mitigation of pandemic influenza: review of cost–effectiveness studies (2009) (29)
An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. (2017) (29)
Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories (2013) (29)
On discounting of health gains from human papillomavirus vaccination: effects of different approaches. (2012) (29)
Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). (2004) (29)
Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults. (2005) (28)
Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement (2016) (28)
Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness? (2004) (28)
Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism (2009) (28)
Profiles of blood and blood component transfusion recipients in Zimbabwe. (2015) (27)
Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review (2016) (27)
Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. (2014) (27)
Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective? (2013) (27)
Long-Acting Methylphenidate-OROS in Youths with Attention-Deficit Hyperactivity Disorder Suboptimally Controlled with Immediate-Release Methylphenidate (2008) (27)
An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model” (2013) (27)
Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations (2016) (27)
Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013. (2015) (27)
Economic evaluations of hepatitis B vaccination for developing countries (2009) (27)
Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam (2001) (26)
The role of economic evaluation in vaccine decision making (2012) (26)
Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada (2018) (26)
Incidence and pattern of 12 years of reported transfusion adverse events in Zimbabwe: a retrospective analysis. (2014) (26)
Discounting health effects in pharmacoeconomic evaluations (2012) (26)
The potential impact of COVID-19 pandemic on the immunization performance in Indonesia (2020) (26)
Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review (2018) (26)
Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrant (2004) (26)
Discounting health effects in pharmacoeconomic evaluations: current controversies. (2005) (26)
Analyzing generic and branded substitution patterns in the Netherlands using prescription data (2011) (26)
The Value of Medicines: A Crucial but Vague Concept (2016) (26)
Cost-effectiveness of HIV screening of blood donations in Accra (Ghana). (2008) (26)
Health-related quality of life in HIV/AIDS patients on antiretroviral therapy at a tertiary care facility in Zimbabwe (2016) (24)
Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs (2009) (24)
COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey (2021) (24)
Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. (2004) (24)
Multivariate Meta-Analysis of Preference-Based Quality of Life Values in Coronary Heart Disease (2016) (23)
Further evidence for favorable cost-effectiveness of elderly influenza vaccination (2006) (23)
Cost-effectiveness of vaccination against herpes zoster (2014) (23)
The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia (2018) (23)
Cost-Analysis of Seven Nosocomial Outbreaks in an Academic Hospital (2016) (23)
Health technology assessments in personalized medicine: illustrations for cost–effectiveness analysis (2011) (22)
Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine (2005) (22)
Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries (2018) (22)
Blood component use in a sub-Saharan African country: results of a 4-year evaluation of diagnoses associated with transfusion orders in Namibia. (2015) (22)
Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account. (2013) (22)
A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season. (2020) (22)
Economics of assisted reproduction: Access to fertility treatments and valuing live births in economic terms (2010) (22)
The pharmacists’ potential to provide targets for interventions to optimize pharmacotherapy in patients with asthma (2013) (22)
Vaccines for tick-borne diseases and cost-effectiveness of vaccination: a public health challenge to reduce the diseases’ burden (2016) (22)
Public health economics of vaccines in the Netherlands: methodological issues and applications (2008) (22)
Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season (2020) (21)
Diabetes distress in Indonesian patients with type 2 diabetes: a comparison between primary and tertiary care (2019) (21)
Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data (2015) (21)
Economic evaluation of meningococcal vaccines: considerations for the future (2019) (21)
Cost-effectiveness of pertussis booster vaccination in the Netherlands. (2012) (21)
Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019 (2021) (20)
Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17 (2020) (20)
Human immunodeficiency virus prevalence, incidence, and residual transmission risk in first‐time and repeat blood donations in Zimbabwe: implications on blood safety (2013) (20)
The Burden of Tick-Borne Encephalitis in Disability-Adjusted Life Years (DALYs) for Slovenia (2015) (20)
Pharmacoeconomics of Influenza Vaccination for Healthy Working Adults (2012) (20)
Cost Effectiveness of Angiotensin Receptor Blocker Monotherapy in Patients with Hypertension in the Netherlands (2010) (20)
Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy (2012) (20)
Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions (2012) (20)
The costs of producing a unit of blood in Zimbabwe (2016) (19)
Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women (2016) (19)
Health-Related Quality of Life of Patients with HPV-Related Cancers in Indonesia. (2018) (19)
Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands. (2017) (19)
Cost-utility of repeated screening for Chlamydia trachomatis. (2008) (19)
Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective (2013) (19)
Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis (2017) (19)
Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events. (2008) (19)
Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. (2011) (19)
Economic evaluations of hepatitis A vaccination in middle-income countries (2013) (19)
Cost of Illness of Chronic Hepatitis B Infection in Vietnam. (2012) (19)
Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives (2015) (19)
Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. (2013) (19)
Stratified Medicine and Reimbursement Issues (2012) (18)
Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model. (2013) (18)
Cost-effectiveness of hepatitis A vaccination in Indonesia (2014) (18)
Health economic methodology illustrated with recent work on Chlamydia screening: the concept of extended dominance (2007) (18)
RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population. (2013) (18)
Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing (2002) (18)
A review of the literature on the economics of vaccination against TB (2012) (18)
Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia. (2016) (18)
Bedside practice of blood transfusion in a large teaching hospital in Uganda: An observational study (2008) (18)
Cost-Effectiveness Analysis of Pneumococcal Vaccination for Elderly Individuals in The Netherlands (2012) (18)
Effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus immunization in Indonesia (2013) (18)
Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza control (2017) (18)
Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment (2018) (18)
Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial) (2015) (18)
Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review (2014) (18)
The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa. (2001) (17)
Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health. (2006) (17)
Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands (2016) (17)
Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies (2011) (17)
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings (2019) (17)
Economic evaluations of adult pneumococcal vaccination strategies (2001) (17)
Discontinuing Inappropriate Medication in Nursing Home Residents (DIM-NHR Study): protocol of a cluster randomised controlled trial (2014) (17)
Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed? (2015) (17)
The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings. (2013) (17)
Combination Vaccine Against Invasive Meningococcal B and Pneumococcal Infections (2006) (17)
Extrapolating Survival Data Using Historical Trial-Based a Priori Distributions. (2019) (17)
Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference. (2018) (17)
TGF-β is an inducer of ZEB 1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion (2014) (17)
The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective (2015) (16)
Modelling the impact of extended vaccination strategies on the epidemiology of pertussis (2011) (16)
The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach. (2007) (16)
Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia (2018) (16)
Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting. (2005) (15)
Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer. (2018) (15)
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. (2007) (15)
Antidepressant use during pregnancy and the risk of developing gestational hypertension: a retrospective cohort study (2018) (15)
Reimbursement of targeted cancer therapies within 3 different European health care systems. (2015) (15)
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making. (2012) (15)
Accelerating the introduction of rotavirus immunization in Indonesia (2014) (15)
Effects of targeting disease and medication management interventions towards patients with COPD (2016) (15)
Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples (2013) (15)
Direct costs of hypertensive patients admitted to hospital in Vietnam– a bottom-up micro-costing analysis (2014) (15)
Economics of vaccines revisited (2013) (15)
Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations (2018) (15)
Cost-effectiveness of screening for proteinuria. (2004) (15)
‘Diabetes is a gift from god’ a qualitative study coping with diabetes distress by Indonesian outpatients (2019) (15)
Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics (2015) (15)
Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria (2017) (14)
Budget constraint and vaccine dosing: a mathematical modelling exercise (2014) (14)
Cost-Effectiveness of Extended-Release Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Sub-Optimally Treated with Immediate Release Methylphenidate (2015) (14)
Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder (2007) (14)
Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines (2018) (14)
A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands. (2003) (14)
Health economic evaluation of gene replacement therapies: methodological issues and recommendations (2020) (14)
Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion. (2017) (14)
Impact of multiple-dose versus single-dose inhaler devices on COPD patients’ persistence with long-acting β2-agonists: a dispensing database analysis (2014) (14)
Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands (2017) (14)
The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. (2009) (13)
Economic evaluation of personalized medicine: a call for real-world data (2017) (13)
Accumulating evidence for the case of differential discounting (2013) (13)
Cost-effectiveness of rotavirus immunization in Indonesia taking breastfeeding patterns into account (2012) (13)
8th European Conference on Rare Diseases & Orphan Products (ECRD 2016) (2016) (13)
Pharmacoinformatics and drug discovery technologies: Theories and applications (2012) (13)
Evidence-based Clinical Decision Support Systems for the prediction and detection of three disease states in critical care: A systematic literature review (2019) (13)
Comparing the EQ-5D-3 L and EQ-5D-5 L: studying measurement and scores in Indonesian type 2 diabetes mellitus patients (2020) (13)
BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles (2016) (13)
Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data (2016) (13)
Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer (2016) (13)
Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands. (2014) (13)
Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease. (2019) (13)
Atrial Fibrillation in Africa-An Underreported and Unrecognized Risk Factor for Stroke: A Systematic Review. (2019) (12)
Cross-border comparison of antibiotic prescriptions among children and adolescents between the north of the Netherlands and the north-west of Germany (2015) (12)
Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. (2019) (12)
Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges (2016) (12)
Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands (2012) (12)
A few years later (2014) (12)
The use of modeling in the economic evaluation of vaccines (2002) (12)
Let’s stop dumping cookstoves in local communities. It’s time to get implementation right (2020) (12)
What's on the mind of IVF consumers? (2009) (12)
COST-EFFECTIVENESS OF SCREENING FOR DIABETES IN A COHORT OFPATIENTS WITH SCHIZOPHRENIA (2008) (12)
The long-term fiscal impact of funding cuts to Danish public fertility clinics. (2011) (12)
Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis (2020) (12)
Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches (2002) (12)
Economic Evaluation of Influenza Vaccination (1999) (12)
Predictors for Starting Depot Administration of Risperidone in Chronic Users of Antipsychotics (2008) (12)
Comparing Cost-Effectiveness Results for a Vaccine Across Different Countries Worldwide: What Can We Learn? (2014) (12)
Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands (2007) (11)
The burden and costs of sepsis and reimbursement of its treatment in a developing country: An observational study on focal infections in Indonesia. (2020) (11)
Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia. (2013) (11)
Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: costeffectiveness analyses and implications for The Netherlands (2003) (11)
Excess drug prescriptions during influenza and RSV seasons in the Netherlands: Potential implications for extended influenza vaccination (2008) (11)
Valuing prevention through economic evaluation (2012) (11)
Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine (2019) (11)
Discounting health benefits (2002) (11)
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier. (2019) (11)
Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections (2012) (11)
Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach (2016) (11)
Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccine in the United States. (2014) (10)
Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project (2020) (10)
Differential Time Preferences for Money and Quality of Life (2014) (10)
Economic Consequences and Potentially Preventable Costs Related to Osteoporosis in the Netherlands. (2017) (10)
HIV-associated dementia: Clinical, epidemiological and resource utilization issues. (1998) (10)
Within-Gender Changes in HIV Prevalence among Adults between 2005/6 and 2010/11 in Zimbabwe (2015) (10)
Health related quality of life impact from rotavirus diarrhea on children and their family caregivers in Thailand (2018) (10)
A Cost Minimization Analysis of Ready-to-Administer Prefilled Sterilized Syringes in a Dutch Hospital. (2019) (10)
Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands (2016) (10)
Updated healthcare cost estimate for drug-related hepatitis C infections in the European Union (2004) (10)
Cost-effectiveness of screening for genital Chlamydia trachomatis (2001) (10)
Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design (2015) (10)
A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season. (2021) (10)
Pharmacoeconomics and market access in Europe: case studies in Scotland and the Netherlands (2006) (9)
Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study (2007) (9)
Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands (2006) (9)
Economics of Transfusion (2002) (9)
Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands (2018) (9)
The health-economic studies of HPV vaccination in Southeast Asian countries: a systematic review (2017) (9)
The Economics of HIV Vaccines (2012) (9)
Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis (2019) (9)
[Screening for asymptomatic Chlamydia trachomatis infection in pregnancy; cost-effectiveness favorable at a minimum prevalence rate of 3% or more]. (2000) (9)
Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands. (2010) (9)
Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes (2012) (9)
Access to anti-cancer drugs in India: is there a need to revise reimbursement policies? (2018) (9)
Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson’s Disease in The Netherlands (2014) (9)
Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia (2020) (9)
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism (2020) (9)
Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands (2019) (8)
Predictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocol (2015) (8)
Cost-Effectiveness of Dengue Vaccination in Indonesia: Considering Integrated Programs with Wolbachia-Infected Mosquitos and Health Education (2020) (8)
Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients (2011) (8)
A personalised screening strategy for diabetic retinopathy: a cost-effectiveness perspective (2020) (8)
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation (2017) (8)
Defining and Measuring the Affordability of New Medicines: A Systematic Review (2017) (8)
Quantifying the impact of mass vaccination programmes on notified cases in the Netherlands (2018) (8)
Optimising Assessments of the Epidemiological Impact in the Netherlands of Paediatric Immunisation with 13-Valent Pneumococcal Conjugate Vaccine Using Dynamic Transmission Modelling (2014) (8)
Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases (2020) (8)
Practical implications of differential discounting of costs and health effects in cost-effectiveness analysis. (2011) (8)
Impact of using different blood donor subpopulations and models on the estimation of transfusion transmission residual risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in Zimbabwe (2016) (8)
Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts (2010) (8)
Models to Predict the Burden of Cardiovascular Disease Risk in a Rural Mountainous Region of Vietnam. (2014) (8)
Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs. (2021) (8)
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review (2021) (8)
The societal role of lifelong vaccination (2015) (8)
Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. (2007) (8)
Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands. (2014) (8)
Namibia's transition from whole blood–derived pooled platelets to single‐donor apheresis platelet collections (2015) (8)
Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji (2018) (8)
Factors associated with the uptake of newly introduced childhood vaccinations in Ethiopia: the cases of rotavirus and pneumococcal conjugate vaccines (2019) (8)
Contents of Next Issues (2002) (8)
The effect of financial and educational incentives on rational prescribing. A state-space approach. (2015) (8)
Contributing factors to influenza vaccine uptake in general hospitals: an explorative management questionnaire study from the Netherlands (2012) (8)
Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing. (2014) (8)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference (2009) (8)
A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention (2012) (8)
The impact of external donor support through the U.S. President's Emergency Plan for AIDS Relief on the cost of red cell concentrate in Namibia, 2004-2011. (2015) (7)
Cost-effectiveness of screening asymptomatic women for Chlamydia trachomatis (2000) (7)
A comparison of average wages with age-specific wages for assessing indirect productivity losses: analytic simplicity versus analytic precision (2016) (7)
Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose? (2022) (7)
Comparing the impact of high-dose versus standard dose influenza vaccines on hospitalization cost for cardiovascular and respiratory diseases: Economic assessment in the US Veteran population during 5 respiratory seasons using an instrumental variable method. (2020) (7)
Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe (2016) (7)
Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States (2021) (7)
[Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment]. (1999) (7)
Multidrug-Resistant Infections Among Hospitalized Adults With Community-Acquired Pneumonia In An Indonesian Tertiary Referral Hospital (2019) (7)
Cost-effectiveness analysis of Human Papillomavirus (HPV) vaccination in the Netherlands: recent publication reinforces favorable cost-effectiveness despite misleading conclusion. (2010) (7)
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial (2021) (7)
Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination (2013) (7)
[Pharmaco-economic evaluation of mandatory HIV-screening in pregnancy; a cost-efficacy analysis in Amsterdam]. (2000) (7)
HIV post-exposure prophylaxis: enhancing its pharmaco-economic profile by discriminate prescribing. (2002) (7)
Cost Effectiveness of Oseltamivir Treatment for Patients with Influenza-Like Illness Who Are at Increased Risk for Serious Complications of Influenza (2012) (7)
Cost-effectiveness analyses of pharmacologic maintenance treatment for chronic obstructive pulmonary disease: A systematic review (2016) (7)
Economic burden of rotavirus diarrhea in Thailand: Report from a pilot study on rotavirus vaccination. (2019) (7)
Budget Impact Analysis of a Renal Point-of-Care Test in Dutch Community Pharmacies to Prevent Antibiotic-Related Hospitalizations (2018) (7)
Evidence-based Clinical Decision Support Systems for the prediction and detection of three disease states in critical care: A systematic literature review. (2019) (7)
Evaluation of health promotion programmes in severe mental illness: theory and practice (2015) (6)
Cost-effectiveness of screening for proteinuria. Autor's reply (2004) (6)
Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies (2020) (6)
Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment. (2016) (6)
Utilities of Patients with Hypertension in Northern Vietnam (2015) (6)
Positive impact of infection prevention on the management of nosocomial outbreaks at an academic hospital. (2016) (6)
Cost-Effectiveness Analysis of BCG Vaccination against Tuberculosis in Indonesia: A Model-Based Study (2020) (6)
Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates (2018) (6)
Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs (2002) (6)
Pharmacoeconomic research (2004) (6)
Adherence of Pharmacoeconomic Studies to National Guidelines in the Netherlands (2005) (6)
Guidelines for pharmaco-economic research in relation to published health-economics evaluations (2002) (6)
Efficiency of Diagnostic Testing for Helicobacter pylori Infections—A Systematic Review (2021) (6)
Incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit (2020) (6)
[Benefit of the serological screening program for syphilis in pregnant women in Amsterdam in the period 1985-1989]. (1991) (6)
Transfusion Medicine: Quo Vadis? What Has Been Achieved, What Is to Be Expected (2001) (6)
Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes (2008) (6)
Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis (2021) (6)
Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. (2020) (6)
Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban (2007) (6)
Health economic evaluation of current vaccination strategies and new vaccines against tuberculosis: a systematic review (2019) (6)
Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program. (2021) (6)
Vaccine market access pathways in the EU27 and the United Kingdom - analysis and recommendations for improvements. (2021) (6)
Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: A scenario analysis for the Netherlands (2011) (6)
Cost-effectiveness of widespread screening for Chlamydia trachomatis (2002) (6)
Estimates of the Global Burden of COVID-19 and the Value of Broad and Equitable Access to COVID-19 Vaccines (2022) (5)
Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups (2022) (5)
Hospital care for p ersons with AIDS in European‐Union countries; a cross‐country comparison (2000) (5)
The average unit production cost of blood in Zimbabwe from a provider's perspective (2014) (5)
Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts. (2022) (5)
Costs and benefits of individuals conceived after IVF: a net tax evaluation in The Netherlands. (2014) (5)
Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital (2008) (5)
Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost–effectiveness in early Parkinson’s disease (2012) (5)
Budget Impact of Increasing Market Share of Patient Self-Testing and Patient Self-Management in Anticoagulation. (2016) (5)
A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019-2020 Influenza Season in the United States. (2021) (5)
Healthcare professional-led interventions on lifestyle modifications for hypertensive patients – a systematic review and meta-analysis (2021) (5)
Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study. (2004) (5)
Economic Burden Of Acute Myocardial Infarction In Vietnam. (2015) (5)
Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review (2019) (5)
Understanding the Improvement in Full Childhood Vaccination Coverage in Ethiopia Using Oaxaca–Blinder Decomposition Analysis (2020) (5)
Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around… (2012) (5)
Do costs of varicella justify routine infant vaccination? (2004) (5)
Health economics of infectious diseases (2009) (5)
Health Care as an Investment: Implications for an Era of Ageing Populations: (2010) (5)
Pharmaco-economic evaluation of universal HIV-screening of pregnant women; a cost-effectiveness analysis for Amsterdam. (2000) (5)
A tailored antiplatelet strategy in STEMI patients based on CYP2C19 genotyping is feasible in daily practice-POPular Genetics study (2014) (5)
Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis (2017) (5)
Dabigatran For The Treatment And Secondary Prevention Of Venous Thromboembolism. (2015) (5)
INCREMENTAL COST PER QUALITY-ADJUSTED LIFE YEAR GAINED? THE NEED FOR ALTERNATIVE METHODS TO EVALUATE MEDICAL INTERVENTIONS FOR ULTRA-RARE DISORDERS (2013) (5)
Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands. (2016) (5)
PIN8 COST-EFFECTIVENESS OF INTERVENTIONS ENSURING BLOOD TRANSFUSION SAFETY IN AFRICA (2006) (5)
Cost-effectiveness of HIV screening of blood donations in Ghana (2006) (5)
Incidence Description and Costs of Acute Heart Failure in the Netherlands. (2014) (5)
Cost-Effectiveness of Scaling Up Modern Family Planning Interventions in Low- and Middle-Income Countries: An Economic Modeling Analysis in Indonesia and Uganda (2018) (5)
Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison (2020) (5)
Dynamic modeling for pandemic influenza (2012) (5)
A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy (2016) (5)
Hepatitis C and injecting drug use (2004) (5)
The impact of patent expiry on drug prices: insights from the Dutch market (2020) (5)
Prevalence and Economic Burden of Respiratory Diseases in Central Asia and Russia: A Systematic Review (2020) (4)
[Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses]. (2009) (4)
Cost-minimization of mabthera intravenous versus subcutaneous administration (2013) (4)
Implementing a context-driven awareness programme addressing household air pollution and tobacco: a FRESH AIR study (2020) (4)
Evaluation of the leukocyte esterase test (LET) as pre-screening test to reduce costs for national population-based Chlamydia trachomatis screening programs. (2006) (4)
Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research (2017) (4)
PCV114 DABIGATRAN ETEXILATE IS COST-SAVING FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS FOLLOWING MAJOR ORTHOPAEDIC SURGERY IN THE NETHERLANDS (2009) (4)
[Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis]. (2002) (4)
Disability-Adjusted Life Years (Dalys) as a Composite Measure to Express the Burden of Tick-Borne Encephalitis (Tbe) in Slovenia. (2014) (4)
[Cost-effectiveness of influenza vaccination The Netherlands]. (1997) (4)
Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands (2020) (4)
IN4 ECONOMIC EVALUATION OF INFLUENZA PANDEMIC MITIGATION STRATEGIES IN THE US USING A STOCHASTIC MICROSIMULATION INFLUENZA MODEL (2007) (4)
Pharmacoeconomic review of recombinant human DNase in the management of cystic fibrosis (2004) (4)
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations (2020) (4)
Consultations for Influenza-Like Illness in Primary Care in The Netherlands: A Regression Approach. (2020) (4)
Investments in blood safety improve the availability of blood to underserved areas in a sub-Saharan African country. (2014) (4)
Cost-effectiveness of a potential anti-tick vaccine with combined protection against Lyme borreliosis and tick-borne encephalitis in Slovenia. (2019) (4)
The mondriaan project: The dutch healthcare landscape as a population laboratory (2010) (4)
Translation, Cross-Cultural Adaptation, Validity, and Reliability of the Indonesian Version of the IKDC Subjective Knee Form (2021) (4)
Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects (2018) (4)
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies (2021) (4)
Health Economics of Vaccines: From Current Practice to Future Perspectives (2020) (4)
Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006. (2010) (4)
Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed? (2021) (4)
School health in Europe: a review of workforce expenditure across five countries (2020) (4)
Cost-Effectiveness of Treatments in Children With Attention-Deficit/Hyperactivity Disorder: A Continuous-Time Markov Modeling Approach (2019) (4)
Meta-analysis of preference-based quality of life values in heart failure (2014) (4)
Cost-effectiveness of paediatric influenza vaccination in the Netherlands (2020) (4)
Estimating the Population-Level Effectiveness of Vaccination Programs in the Netherlands (2017) (4)
Costs of chemotherapy in the treatment of colorectal cancer (2006) (4)
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting (2021) (4)
Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada” (2018) (3)
Exploring patient satisfaction after operative and nonoperative treatment for midshaft clavicle fractures: a focus group analysis (2020) (3)
Cost-Effectiveness of Human Papillomavirus Vaccination Programmes Parallel to Current Routine Vaccination of Young Teenage Girls. (2014) (3)
Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands (2017) (3)
Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium (2018) (3)
Cost-Effectiveness Of Culture-Based Versus Empirical Antibiotic Treatment For Hospitalized Adults With Community-Acquired Pneumonia In Indonesia: A Real-World Patient-Database Study (2019) (3)
Inequalities in Rotavirus Vaccine Uptake in Ethiopia: A Decomposition Analysis (2020) (3)
Cost analysis of outbreaks with Methicillin-resistant Staphylococcus aureus (MRSA) in Dutch long-term care facilities (LTCF) (2018) (3)
Reimbursement of Targeted Cancer Therapies Within Three Different European Health Care Systems. (2014) (3)
Multi-criteria decision analysis to prioritize the introduction of new vaccines in Indonesia by using the framework of the strategic multi-attribute ranking tool for vaccines (SMART vaccines) (2021) (3)
IN4 DISCOUNTING HEALTH BENEFITS:A NOVEL APPROACH TO ENSURE PROPER VALUING OF VACCINATION STRATEGIES (2002) (3)
Assesing The Net Fiscal Consequences Of Tobacco Use In A High Consumption And High Tobacco Tax Country: The Case Of Greece. (2015) (3)
PGI2 THE ECONOMIC EVALUATION OF A RANDOMIZED TRIAL COMPARING “TEST-AND-TREAT” WITH PROMPT ENDOSCOPY IN PRIMARY CARE; THE HEALTH ECONOMICS OF THE SENSE-STUDY (2004) (3)
Economics and vaccines (2009) (3)
Investments in blood safety improve the availability of blood to underserved areas in a sub‐Saharan African country (2014) (3)
The Application of Cost Effectiveness Analysis to Derive a Formulary for Urinary Tract Infections (2002) (3)
Translation, adaptation and validation of the diabetes distress scale for Indonesian diabetic outpatients with various types of complications (2016) (3)
An alternative parameterization of Bayesian logistic hierarchical models for mixed treatment comparisons (2015) (3)
[Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance]. (2010) (3)
Burden of Early and Advanced Breast Cancer in The Netherlands (2016) (3)
Pharmo-economics of drug addiction: estimating the costs of hepatitis C virus, hepatitis B virus and human immunodeficiency virus infection among injecting drug users in member States of the European Union (2002) (3)
Trends in governmental expenditure on vaccination programmes in the Netherlands, a historical analysis. (2019) (3)
Epidemiological Models and Socioeconomic Information: Methodological Aspects of AIDS/HIV Scenario Analysis (1990) (3)
Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review (2021) (3)
The Role of Administrative and Secondary Data in Estimating the Costs and Effects of School and Workplace Closures due to the COVID-19 Pandemic (2020) (3)
Perioperative bridging of vitamin K antagonist treatment in patients with atrial fibrillation: only a very small group of patients benefits. (2019) (3)
The economic profile of antenatal HIV testing: pharmaceutical and methodological considerations. (2003) (3)
PHP13: PHARMACOECONOMICS OF BLOOD TRANSFUSION SAFETY MEASURES: A REVIEW OF THE LITERATURE (2001) (3)
Expanding access to non-traditional vaccines: a perspective from Indonesia (2014) (3)
AIDS up to the Year 2000 (1992) (3)
Quality Of Life Of Diarrheal Children And Caregivers In Thailand. (2014) (3)
Identification and expert panel rating of key structural approaches applied in health economic obesity models (2020) (3)
Discounting Health Effects in Pharmacoeconomic Evaluations: Some Additional Elements to Consider (2003) (3)
On the Causal Interpretation of Rate-Change Methods: The Prior Event Rate Ratio and Rate Difference (2020) (3)
Networks for improving care in patients with acute coronary syndrome: A framework (2014) (3)
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands. (2022) (3)
Rotavirus Vaccination of Infants Delayed and Limited within the National Immunization Programme in the Netherlands: An Opportunity Lost (2020) (2)
PCV85 Cost-Effectiveness of Increasing Statin Adherence for Secondary Prevention in Community Pharmacies (2011) (2)
Pharmaco-economics of transfusion safety (2001) (2)
A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients. (2020) (2)
Reconstructing the Effectiveness of Policy Measures to Avoid Next-Wave COVID-19 Infections and Deaths Using a Dynamic Simulation Model: Implications for Health Technology Assessment (2022) (2)
Stakeholder opinions on value in healthcare (2017) (2)
PMH14 DUTCH ADAPTION OF THE COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE MANIA IN BIPOLAR I DISORDER (2005) (2)
Prospective multicentre observational cohort to assess quality of life, functional outcomes and cost-effectiveness following minimally invasive surgical techniques for rectal cancer in ‘dedicated centres’ in the Netherlands (VANTAGE trial): a protocol (2022) (2)
Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence (2018) (2)
DISCOUNTING HEALTH EFFECTS (2010) (2)
Age Should Women Be Vaccinated Against HPV Infection ? Recommendation Based on Cost-effectiveness Analyses (2011) (2)
Cost-Effectiveness of Universal Vaccination Against Varicella in the Netherlands (2013) (2)
Screening for asymptomatic infection with Chlamydia trachomatis in pregnancy; favourable cost-effectiveness if prevalence is 3% or more. (2000) (2)
Early cost-effectiveness analysis of screening for preeclampsia in nulliparous women: A modelling approach in European high-income settings (2022) (2)
Methods for Health Economic Evaluations of Vaccines - Results from an International Expert-Workshop. (2014) (2)
Response on "RE: Cost-effectiveness of pertussis booster vaccination in the Netherlands". (2013) (2)
Using subpopulation treatment effect pattern plot to identify more efficient resource allocation policies (2016) (2)
Cost-Effectiveness Of A Potential Combined Vaccine Against Lyme Borreliosis And Tick-Borne Encephalitis In Slovenia (2017) (2)
Net monetary benefit (2009) (2)
Informing decision makers seeking to improve vaccination programs: case-study Serbia (2021) (2)
Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes (2003) (2)
Cost-effectiveness of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in The Netherlands (2006) (2)
PCN64 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING METHODOLOGIES ADJUSTING FOR OVERALL SURVIVAL IN THE PRESENCE OF TREATMENT SWITCHING (2018) (2)
PCN64 COST-EFFECTIVENESS OF IMATINIB SINCE ITS INTRODUCTION AS FIRST-LINE TREATMENT IN THE NETHERLANDS (2019) (2)
Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. (2022) (2)
Further approaches to reduce the cost of renal replacement therapy (2017) (2)
The evaluation of blood donor deferral causes in Zimbabwe (2013) (2)
Cost-Effectiveness of Hepatitis a Vaccination in Indonesia. (2014) (2)
Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review. (2009) (2)
The ‘Dynamic’ Marriage Between Varicella and Zoster (2015) (2)
EMCDDA Monographs. Hepatitis C and injecting drug use: impact, costs and policy options (2004) (2)
Internet and computer use amongst european pharmacy undergraduates : Exploring similarities and differences (2017) (2)
Economic Assessment of Preeclampsia: Screening, Diagnosis, Treatment Options, and Long Term Outcomes, A Systematic Review. (2014) (2)
Cost-effectiveness of hepatitis B immunization in Vietnam (2012) (2)
Micro-costing study of rituximab subcutaneous injection versus intravenous infusion in dutch setting (2015) (2)
Cost-Effectiveness of HIV NAT Screening for Dutch Donors (2001) (2)
VA5 INDIVIDUALLY-BASED DYNAMIC MODELING OF INFECTIOUS DISEASES: COST-EFFECTIVENESS OF ADOLESCENT PERTUSSIS BOOSTER VACCINATION FOR THE NETHERLANDS (2009) (2)
The pharmacoeconomics of alternatives to allogeneic blood transfusion (2004) (2)
Cost-Effectiveness Analysis for Apixaban in The Acute Treatment and Prevention of Venous Thromboembolism in The Netherlands (2016) (2)
Health Economics of Interventions to Tackle the Coronavirus 2019 Pandemic (2021) (2)
The application of multi-criteria decision analysis to inform in resource allocation (2020) (2)
A population based dynamic approach for estimating the cost effectiveness of screening for Chlamydia trachomatis (2003) (2)
HIV-associated dementia: clinical, epidemiological and resource utilization issues. (1998) (2)
Late Breaking Abstract - Health economic burden of asthma/COPD in Uganda, Vietnam, Kyrgyzstan and Greece : FRESH AIR results (2017) (2)
Effectiveness and acceptability of a smart inhaler asthma self-management programme: a cluster RCT study protocol (2019) (2)
PIN51 UPDATING THE COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION IN THE NETHERLANDS (2010) (2)
Socio-economic aspects of extended STD screening in pregnancy (2000) (2)
PHP34 ECONOMICS OF TRANSFUSION (2002) (2)
Publisher Correction: Implementing a context-driven awareness programme addressing household air pollution and tobacco: a FRESH AIR study (2020) (2)
Cost-effectiveness of statins for primary prevention in newly diagnosed type 2 diabetes patients in the Netherlands (2013) (2)
PIN45 COST-EFFECTIVENESS OF A COCOONING IMMUNIZATION STRATEGY AGAINST PERTUSSIS FOR THE NETHERLANDS (2009) (2)
Reviewing and piloting methods for decreasing discount rates; someone, somewhere in time (2013) (2)
[Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women]. (1999) (2)
PUK12 COST-EFFECTIVENESS OF ACE INHIBITOR THERAPY TO PREVENT DIALYSIS IN NON-DIABETIC NEPHROPATHY—INFLUENCE OF THE ACE INSERTION / DELETION POLYMORPHISM (2009) (1)
Cost-effectiveness of antenatal HIV-testing: reviewing its pharmaceutical and methodological aspects (2004) (1)
VA8 HOW SHOULD HEALTH GAINS OF VACCINATION STRATEGIES BE DISCOUNTED (2009) (1)
Performing diagnostics, especially blood cultures, on-time for infectious patients reduces length of stay and costs (2015) (1)
CV3 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN GERMANY: APPLYING THE EFFICIENCY THRESHOLD (2018) (1)
Cost-effectiveness of alternatives to allogeneic blood transfusion; Reviewing the available evidence (2002) (1)
Abstract 11651: Cost-effectiveness of Screening for Atrial Fibrillation in Primary Care With a Hand-held, Single-lead ECG Device in the Netherlands (2016) (1)
The silent socioeconomic impact of COPD/asthma in Africa, Asia and Europe – a FRESH AIR study (2018) (1)
The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data. (2022) (1)
Administration Advantages and Cost-Savings with Dabigatran Etexilate Versus Parenteral Agents for Thromboprophylaxis After Major Orthopaedic Surgery in the Netherlands. (2009) (1)
Economic Analysis of Scaling Up Access to Modern Family Planning Methods in Low and Middle-Income Countries; Case Studies for Indonesia and Uganda (2016) (1)
PIN132 HEALTH-ECONOMIC MODELLING OF INFECTIOUS DISEASE DIAGNOSTICS: CURRENT APPROACHES AND FUTURE OPPORTUNITIES (2019) (1)
Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration (2018) (1)
PIN17 COST-EFFECTIVENESS OF MASS VACCINATION FOR VARICELLA IN FRANCE WITH MMRV VERSUS MMR (2008) (1)
Cost-effectiveness of long acting methylphenidate-OROS in ADHD youths with suboptimal symptom control on immediate-release methylphenidate in The Netherlands (2006) (1)
The European Social Preference Measurement (ESPM) Study: Conceptual Considerations and Implementation (2016) (1)
PCV34 COST-EFFECTIVENESS OF PATHOGEN INACTIVATION FOR PLATELET TRANSFUSIONS IN DUTCH CARDIAC SURGERY (2002) (1)
The authors' reply. (Discounting health effects in pharmacoeconomic evaluations: current controversies. Birks, S. Pharmacoeconomics 2006;24(12)1273-4 ) (2006) (1)
A systematic literature review of the cost-effectiveness of erythropoietin in orthopedic surgery: There is a need for differentiation between total hip and knee arthroplasty (2015) (1)
The Impact of Extrapolating Survival Based on Cure Models: Comparing Mean Incremental Survival and Cure Rates in Different Datasets (2016) (1)
ASSESSING THE BROADER IMPACT OF VACCINATIONS (2012) (1)
A Qualitative Study: Early Detection of Breast Cancer in Indonesia (After Universal Health Coverage Implementation) (2021) (1)
PCN53 - Access to Anti-Cancer Drugs In India: Is There a Need to Revise Reimbursement Policies? (2016) (1)
Inclusion Of Safety/ADR-Related Outcomes In Economic Evaluations For Seasonal Influenza Vaccines: A Review Of Available Studies (2017) (1)
Economic Burden Of Vaccine Preventable Infectious Diseases Among Elderly Patients In Dutch Hospitals (2017) (1)
PCN13 Analysis of the Impact of Prophylactic Vaccination Against Human Papillomavirus Infection Using a Dynamic-Modelling Approach (2012) (1)
Cost-effectiveness of losartan in patients with hypertension and LVH : An economic evaluation for the Netherlands based on the LIFE-study (2005) (1)
A Systematic Literature Review of The Economic Implications of Acute Bacterial Skin And Skin Structure Infections (Absssis). (2015) (1)
PMS42 Cost-Effectiveness of Increasing Bisphosphonates Adherence for Osteoporosis in Community Pharmacies (2011) (1)
PUK26 THE INFLUENCE OF FUTURE UNRELATED COSTS ON COSTEFFECTIVENESS ESTIMATES:TREATMENT OF HYPERPHOSPHATEMIA WITH LANTHANUM CARBONATE IN PRE-DIALYIS PATIENTS WITH CHRONIC KIDNEY DISEASE (2010) (1)
PGI7 COST-EFFECTIVENESS OF A POTENTIAL FUTURE HELICOBACTER PYLORI VACCINE IN THE NETHERLANDS (2006) (1)
Modelling the Cost-Effectiveness of Implementing a Dietary Intervention in Renal Transplant Recipients (2021) (1)
[Dutch Institute for Health Care Improvement revised guideline, 'Sexually transmitted diseases and neonatal herpes']. (2003) (1)
The Tripartite insurance model (TIM): A financial incentive to prevent outbreaks of infections due to multi-drug resistant microorganisms in hospitals. (2021) (1)
Is a deep response the key to successful treatment of multiple myeloma (2015) (1)
PMH7 USING DRUG DISPENSING DATA TO STUDY THE VALIDITY OF PARASKAVEDEKATRIAPHOBIA (2010) (1)
Core health-components, contextual factors and program elements of community-based interventions in Southeast Asia – a realist synthesis regarding hypertension and diabetes (2021) (1)
PMC31 THE MONDRIAAN PROJECT: THE DUTCH HEALTH CARE LANDSCAPE AS A POPULATION LABORATORY (2009) (1)
PCN63 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING MATCHING-ADJUSTED INDIRECT COMPARISONS AND SIMULATED TREATMENT COMPARISONS (2018) (1)
PCN10 COST ANALYSIS OF CAPECITABINE VERSUS 5-FU/LV FOR COLORECTAL CANCER PATIENTS IN THE NETHERLANDS (2002) (1)
Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand (2021) (1)
Expressing the burden of tick-borne encephalitis (TBE) in disability-adjusted life years (DALYs) in Slovenia (2015) (1)
The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands (2020) (1)
Inclusion Of Costs And Effects Related To Toxicity/Safety In Cost -Effectiveness Analysis; An Illustration For Influenza Vaccines (2016) (1)
Pharmacoeconomics and market access in Europe (2006) (1)
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies (2020) (1)
Pharmaco-economic Review of Recombinant Human DNase (rhDNase) in the management of Cystic Fibrosis; with special reference to current developments in delivery systems (2009) (1)
Clinical Characteristics, Treatment Patterns and Economic Burden of COPD in Kyrgyzstan: A FRESH AIR Study (2021) (1)
PUK25 USING GENETIC POLYMORPHISM AS A STRATEGY TO ESTIMATE THE POTENTIAL COST-EFFECTIVENESS OF PHARMACOLOGICAL CCR5 BLOCKADE IN DIALYSIS PATIENTS (2010) (1)
Medication availability and economic barriers to adherence in asthma and COPD patients in low-resource settings (2022) (1)
IN5 ECONOMIC EVALUATION OF A LARGE-SCALE MENINGOCOCCAL C VACCINATION PROGRAM IN THE NETHERLANDS (2002) (1)
IN3 METHODS FOR ASSESSING COSTS AND EFFECTS OF ANTIRETROVIRAL THERAPIES IN HIV:THE IMPACT OF USING AN EXTENDED STUDY PERIOD (2002) (1)
PCN59 - ASSOCIATION BETWEEN HAZARD RATIOS OF SURROGATE TIME-TO-EVENT ENDPOINTS AND OVERALL SURVIVAL IN ADVANCED/METASTATIC CANCERS (2018) (1)
Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges (2021) (1)
Diagnostic Testing for Sepsis: A Systematic Review of Economic Evaluations (2021) (1)
VA4 COST-EFFECTIVENESS OF UNIVERSAL HEPATITIS B IMMUNIZATION IN VIETNAM: APPLICATION OF COST-EFFECTIVENESS AFFORDABILITY CURVES IN HEALTH DECISION-MAKING (2010) (1)
PMU102 Western-World Hospitalization Implementation Examples of VALUE-Based Healthcare in Expensive Intervention Settings: A Systematic Review (2020) (1)
Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands (2012) (1)
PIH21 IS ROUTINE IMMUNIZATION OF ELDERLY WITH THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE LIKELY TO BE CONSIDERED AS COST-EFFECTIVE? (2010) (1)
Innovative medicines & managed entry agreements; a happy marriage? (2020) (1)
PGU4: UTILIZATION AND COSTS OF GASTROINTESTINAL DRUGS IN RELATION TO HELICOBACTER-PYLORI ERADICATION; PHARMACOECONOMIC ANALYSIS FOR THE NETHERLANDS (2000) (1)
PHP21: COST-BENEFIT ANALYSIS OF PREVENTING PRESCRIBING ERRORS BY HOSPITAL PHARMACISTS (2001) (1)
Maximising the potential of HPV vaccines. (2020) (1)
Comparison of blood services and clinical transfusion practices in Zimbabwe and the Netherlands: What are the key lessons? (2014) (1)
Corrigendum to 'A report on the status of vaccination in Europe' [Vaccine 36 (2018) 4979-4992]. (2019) (1)
Cost analysis and cost-effectiveness of open versus laparoscopic versus robot-assisted versus transanal total mesorectal excision in patients with rectal cancer: a protocol for a systematic review (2022) (1)
PDB39 - EMPAGLIFLOZIN FOR PATIENTS IN THE NETHERLANDS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE: A BUDGET IMPACT MODEL (2018) (1)
[Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations]. (2002) (1)
Cost-effectiveness of Itraconazole for the prophylaxis of invasive fungal infections for neutropenic patients; A study for 3 European countries. (2005) (1)
Cost-effectiveness of interventions to prevent , screen and treat chronic diseases : A review (2014) (1)
Cost-effectiveness analysis of a pharmacist-led intervention on improving inhaler adherence in patients with chronic obstructive pulmonary disease (2014) (1)
PIN3 RELATIVE VACCINE EFFECTIVENESS OF QUADRIVALENT CELL-BASED VERSUS EGG-BASED INFLUENZA VACCINES AMONG ADULTS 50-64 YEARS OLD: A U.S. OBSERVATIONAL COHORT STUDY (2020) (1)
COST-EFFECTIVENESS OF UNIVERSAL HEPATITIS B IMMUNIZATION IN VIETNAM (2010) (1)
Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia. (2022) (1)
The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders (2019) (1)
Assessment of the economic impact of aids at national and multi-national level : development of a scenario-analytic approach to support health-care policy (1998) (1)
COST-OF-ILLNESS OF CHRONIC HEPATITIS B INFECTION IN VIETNAM (2010) (1)
Health care and medical technology (1992) (1)
[Optimizing pharmacotherapy in patients with COPD by community-pharmacists: a cost-effectiveness analysis]. (2014) (1)
INDIVIDUALLY-BASED DYNAMIC MODELING OF INFECTIOUS DISEASES (2009) (1)
PIN78 Cost Utility of Infant Vaccination Against Respiratory Syncytial Virus Infection in the Netherlands (2011) (1)
Cardiovascular Risk, Gender And Medication Adherence In Rural Area Of Vietnam. (2014) (1)
Comparative Cost-Effectiveness of Drugs in Early Versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer. (2015) (1)
Evidence-based Clinical Decision Support Systems for the prediction and detection of three disease states in critical care: A systematic literature review [version 2; peer review: 2 approved] (2021) (1)
PIN34 Cost-Effectiveness of Respiratory Syncytial Virus (RSV) Vaccination of Dutch Elderly (2011) (1)
Estimating study costs for use in VOI, a study of dutch publicly funded drug related research (2016) (1)
Interventions for Ultra-Rare Disorders (URDs) and the logic of cost effectiveness (2015) (1)
Possible Role of Cost-Effectiveness of HPV Vaccination within the Decision Context on Inclusion of HPV in the Country-Specific National Immunization Programs (2010) (1)
Objective response rate and progression-free survival as surrogate endpoints for overall survival and the impact of crossover and unbalanced post-progression treatments: A systematic review and meta-analysis in second- and further-line therapy of advanced non-small cell lung cancer (2017) (1)
A systematic review on lifestyle change interventions performed by health care professionals targeting blood pressure in hypertensive patients (2017) (1)
HP4 DRUG COSTS DEVELOPMENT AFTER PATENT EXPIRY IN THE THE NETHERLANDS (2004) (1)
Cost-of-illness of chronic hepatitis B in Vietnam (2012) (1)
How can a Multilevel Promotion of Breastfeeding Reduce the Required Budget for Rotavirus Vaccination in Indonesia? (2014) (1)
Clinical and economic burden of drug-susceptible tuberculosis in Indonesia: national trends 2017-19. (2022) (1)
Sustainability of public finances: inclusion of unrelated medical cost only part of the story (2019) (1)
Modern infectious disease epidemiolgy (2010) (1)
Pharmacoeconomic Research and Application In 10 Asian Countries Between 2003 and 2013: A Systematic Review. (2014) (1)
The Authors’ Reply (2012) (0)
PRM15 Assessing the Broader Impact of Vaccinations: A Government Perspective Quantitative Analytic Framework Applied to Vaccination (2012) (0)
PD49 Burden And Cost Of Anterior Cruciate Ligament Reconstruction And Reimbursement Of Its Treatment In Indonesia: An Observational Study (2022) (0)
PIN9: COST-BENEFIT ANALYSIS OF VACCINATING HEALTHY WORKING ADULTS AGAINST INFLUENZA IN THE NETHERLANDS (2001) (0)
PIN15 Trends in Varicella-Zoster Incidence in the Netherlands & Boosting Effect Within Households (2011) (0)
Baseline analysis of sociocultural aspects of AIDS: 1982-1991 (1992) (0)
PDB15 THE COST OF HYPOGLYCAEMIA IN TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS (2019) (0)
The long-term fiscal impact of changes to reimbursement of assisted reproduction on government accounts in Denmark (2011) (0)
ON7 TIME-TO-TREATMENT DISCONTINUATION (TTD) AS A PRAGMATIC PREDICTOR OF OVERALL SURVIVAL (OS) IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) - REAL-WORLD PERSPECTIVE (2019) (0)
PND46 PREDICTORS OF HEALTH UTILITY IN RELAPSING-REMITTING AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: IMPLICATIONS AND APPLICATIONS FOR FUTURE ECONOMIC MODELS OF DISEASE-MODIFYING THERAPIES (2020) (0)
PIN16 COST-EFFECTIVENESS OF A PROPHYLACTIC HUMAN PAPILLOMA VIRUS 16/18 VACCINE FOR 12-YEAR-OLD DUTCH GIRLS (2008) (0)
Accelerating the introduction of rotavirus immunization in (2014) (0)
AC2 - USE OF MEDICINE PRICING AND REIMBURSEMENT POLICIES FOR UNIVERSAL HEALTH COVERAGE IN INDONESIA (2018) (0)
THE MONDRIAAN PROJECT (2009) (0)
Cancer incidence and mortality in Serbia 1999-2007 (2012) (0)
PMD32 Cost Effectiveness of Cervical Cancer Screening in Serbia: A Comparison of Screening Policies (2011) (0)
10 Years Of Reimbursement Decisions In The Netherlands: An Overview (2017) (0)
PHP20 SWITCH PATTERNS AROUND PATENT EXPIRY WITH ECONOMIC IMPLICATIONS FOR THE NETHERLANDS (2006) (0)
PIN37 - COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION IN THE NETHERLANDS – A DISEASE TRANSMISSION DYNAMIC MODELING APPROACH (2018) (0)
PIN44 COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN THE DUTCH NATIONAL INFLUENZA PREVENTION PROGRAM (2019) (0)
Cost-effectiveness of influenza vaccination in the elderly with inclusion of indirect medical costs (2012) (0)
Health utilities of hypertensive patients in Vietnam (2015) (0)
Poster #S267 IMPROVING SOMATIC HEALTH OF OUTPATIENTS WITH SEVERE MENTAL ILLNESS (2014) (0)
Cost-Utility Of Liquid Chromatography -Tandem Mass Spectrometry (LC-MS/MS)-Based Urine Analyses To Improve Adherence To Antihypertensive Treatment (2017) (0)
University of Groningen Discontinuing Inappropriate Medication in Nursing Home Residents ( DIM-NHR Study ) (2014) (0)
VA1 A European-Wide Study on the Role of Streptococcus Pneumoniae in Community-Acquired Pneumonia among Adults: A Meta-Analysis (2012) (0)
PIN5 UNDERESTIMATION OF VARICELLA INCIDENCE IN THE NETHERLANDS (2009) (0)
PRM111 - APPLICATION AND ACCEPTANCE OF COMPLEX SURVIVAL EXTRAPOLATION METHODS IN HTA SUBMISSIONS (2018) (0)
NM1 A Comparison on Different Network-Meta Analysis (NMA) Models Using Randomized Clinical Trials (RCTS) in Transplant-Ineligible (TIE) NEWLY Diagnosed Multiple Myeloma (NDMM) (2020) (0)
ON THE PROBABILITY OF INTERTEMPORAL INDIFFERENCE (2012) (0)
PCN410 USE OF EXTERNAL INFORMATION FROM HISTORICAL TRIAL DATA TO IMPROVE SURVIVAL ESTIMATIONS ON IMMATURE SURVIVAL DATA IN MULTIPLE MYELOMA (MM) (2019) (0)
ID2: COST-EFFECTIVENESS ANALYSIS OF HEXAVALENT MENINGOCOCCAL B OUTER-MEMBRANE-VESICLE VACCINE (2000) (0)
University of Groningen Cost-minimization model of a multidisciplinary Antibiotic Stewardship Team based on a successful implementation on a urology ward of an academic hospital Dik, (2015) (0)
Trial efficacy vs real world effectiveness in first line treatment of multiple myeloma (2015) (0)
Country score tool to assess readiness and guide evidence generation of immunization programs in aging adults in Europe (2023) (0)
Sustainability of public finances: inclusion of unrelated medical cost only part of the story (2019) (0)
PAR7 PHARMACOECONOMICS OF COX-2-SELECTIVE INHIBITORS VERSUS NON-SELECTIVE NSAIDS AND CONCOMITANT COUMARIN USE: ECONOMIC EVALUATION LINKED TO A CASECONTROL STUDY (2003) (0)
Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer (2016) (0)
PCV30 COST-EFFECTIVENESS OF NOACS IN PATIENTS WITH ATRIAL FIBRILLATION: USING REAL-WORLD DATA FOR EXTERNAL VALIDATION (2019) (0)
PHM6 SOCIETAL COSTS OF ALLOGENEIC BLOOD TRANSFUSION IN THE NETHERLANDS (2006) (0)
University of Groningen Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers Vonkeman, (2009) (0)
Costs of ownership of ready-to-administer pre-filled sterilized syringes in a Dutch hospital: A cost minimization analysis (2017) (0)
PCN372 METHODOLOGIES FOR ADJUSTMENT OF THE TRIAL OVERALL SURVIVAL FOR TREATMENT SWITCHING: A REVIEW OF NICE SUBMISSIONS (2019) (0)
Costs of Clinical Events in Diabetes Type 2 Patients in the Netherlands: A Systematic Review (2017) (0)
Posters (2006) (0)
Specificities of health economics in the area of vaccines evaluation (2014) (0)
Pharmaco-economics of gastro-intestinal drugs (2007) (0)
PIH21 COST-EFFECTIVENESS OF PAEDIATRIC PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS; AN UPDATE FOR THE 7-VALENT AND FORECAST FOR THE 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINES (PCVS) (2009) (0)
Economic Assessment of High-Dose Versus Adjuvanted Influenza Vaccine: An Evaluation of Hospitalization Costs Based on a Cohort Study (2021) (0)
Beyond Cervical Cancer: The Cost-Effectiveness Of Hpv Vaccination In The Netherlands (2016) (0)
University of Groningen Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis Vegter, (2011) (0)
PIN1 A COMPARATIVE NETWORK META-ANALYSIS OF STANDARD OF CARE TREATMENTS IN TREATMENT-NAIVE CHRONIC HEPATITIS B PATIENTS (2020) (0)
Adaptation and Validation of The HIV-Kq-18 HIV Knowledge Questionnaire for Healthy Indonesian Population (2021) (0)
Costs and effects of chlamydial screening programs (2004) (0)
Challenges of using HIV as a primary risk indicator: Need for integrated blood donor risk management model (2015) (0)
Evidence-implementation gaps in low- and middle-income countries' COPD guidelines (2020) (0)
Scenario project “The sociocultural and economic impact of AIDS: design and working plan” (1992) (0)
University of Groningen Modelling the Costs and Effects of Selective and Universal Hospital Admission Screening for Methicillin-Resistant Staphylococcus aureus (2011) (0)
Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands (2021) (0)
PIN72 Cost-Effectiveness of Rotavirus Immunization in Vietnam: Results and Challenges (2011) (0)
PCN286 HEALTH TECHNOLOGY ASSESSMENT DECISIONS OVER THE LAST DECADE IN THE UNITED KINGDOM AND THE NETHERLANDS - A FOCUS ON NON-SMALL-CELL LUNG CANCER (2019) (0)
MT4 MIXED TREATMENT COMPARISON (MTC) OF ANTIFUNGAL DRUGS FOR PROPHYLAXIS TREATMENT AGAINST INVASIVE FUNGAL INFECTIONS (IFIS) IN PATIENTS RECEIVING CHEMOTHERAPY FOR HEMATOLOGICAL MALIGNANCIES OR ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION (2010) (0)
PIN28 COST EFFECTIVENESS ANALYSIS OF BACILLUS CALMETTE-GUÃ‰RIN VACCINATION IN INDONESIA (2019) (0)
PCN316 - RELATIONSHIP BETWEEN TWO CANCER CLINICAL BENEFIT FRAMEWORKS AND HEALTH TECHNOLOGY DECISIONS IN THREE EUROPEAN COUNTRIES (2018) (0)
To Bridge or Not to Bridge : Modelling Periprocedural Anticoagulation Management (2018) (0)
Health Economics of Vaccines: Challenges posed by Regional Differences (2018) (0)
Modelling the Antidepressant's Market Behavior After Patent Expiries: Evidence from the Netherlands (2007) (0)
Financial model based on a successful implementation of a day-2 intervention by a multidisciplinary Antimicrobial Stewardship-Team on a urology ward (2015) (0)
OP28 Health Technology Assessment: A Situation Analysis Of Zimbabwe (2022) (0)
Economic evaluation of apixaban for the prevention of stroke in atrial fibrillation in the Netherlands (2013) (0)
PCN441 NEW METHODOLOGY IN NETWORK META-ANALYSIS USING MIXTURE CURE MODELS (2019) (0)
The role of pharmaco-ecoinformatics in enhancing the pharmaco-economics context of decision making (2012) (0)
PART II HEALTH-ECONOMIC OUTCOMES FOR ALBUMINURIA SCREENING IN REAL-LIFE SETTINGS (2009) (0)
PCN143 - HEALTH ECONOMIC EVALUATION OF BIOLOGIC AGENTS FOR METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL (2018) (0)
Bayesian Methodology Considering Historical Data To Predict Overall Survival From Immature Trial Data In Oncology (2017) (0)
Reviewing cost-effectiveness of HPV- vaccination on top of screening in the specific Dutch context (2017) (0)
Quasi-Monte Carlo Simulation and Variance Reduction Techniques Substantially Reduce Computational Requirements of Patient-Level Simulation Models: an Application to a Discrete Event Simulation Model. (2014) (0)
Table of Contents (2021) (0)
PIN29 ECONOMIC EVALUATION OF MENINGOCOCCAL C VACCINATION PROGRAMMES AND ITS IMPACT ON DECISION MAKING (2004) (0)
Pharmacoeconomics of COX-2-selective inhibitors versus non-selective NSAIDs and concomitant coumarin use (2003) (0)
Reply to Anglemyer et al (2021) (0)
screening for Chlamydia trachomatis (2002) (0)
A probabilistic theory for intertemporal indifference (2014) (0)
PRM233 - THE USE OF THE TWO-STAGE METHOD IN ADJUSTING FOR TREATMENT CROSSOVER. A SIMULATION STUDY. (2018) (0)
PCV38 COST-EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH HYPERTENSION: A COMPARATIVE ANALYSIS USING CLINICAL TRIAL AND OBSERVATIONAL DATA (2007) (0)
PHP205 - BARRIERS TO AND FACILITATORS OF THE APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN MEDICINE PRICING AND REIMBURSEMENT POLICIES IN INDONESIA (2018) (0)
A consistent relaxation of the consumption invariant rate in the discounted-utility model (2013) (0)
PIN25 COST-EFFECTIVENESS OF A PHARMACY-BASED SCREENING FOR CHLAMYDIA TRACHOMATIS (2003) (0)
Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands (2022) (0)
A novel perspective on pharmaceutical R&D costs: opportunities for reductions (2021) (0)
Assessing the Broader Economic Consequences of Hpv Prevention in Indonesia Using a Government Perspective Fiscal Analytic Method (2016) (0)
Relative vaccine effectiveness of adjuvanted trivalent influenza vaccine compared to egg-based trivalent high dose and other egg-based vaccines (2020) (0)
Cost-Effectiveness analysis of Quadrivalent Versus trivalent Influenza Vaccination In Germany - Linking a Dynamic Transmission Model with Health and Economic Outcomes. (2015) (0)
Cost-Effectiveness Analysis Of A Point-Of-Care Test For Renal Function Measurement In Community Pharmacies In The Netherlands To Prevent Antibiotic-Related Hospitalizations (2017) (0)
Comparison Of Standard Parametric Survival Methods Versus More Flexible Approaches (2017) (0)
SELECTED ORAL COMMUNICATION SESSION, SESSION 73: EPIDEMIOLOGY & HEALTH ECONOMICS Wednesday 6 July 2011 14:00 – 15:45 (2011) (0)
University of Groningen Cost-Effectiveness Analysis of Various Pertussis Vaccination Strategies Primarily Aimed at Protecting Infants in the Netherlands Westra, (2010) (0)
TCRM_A_260377 969..977 (2020) (0)
PIN115 ANALYZING SOCIO-ECONOMIC INEQUALITY IN CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA (2019) (0)
Persistent Socioeconomic Inequalities in Measles Vaccine Uptake in Ethiopia in the Period 2005 to 2016. (2021) (0)
The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention (2016) (0)
Meningococcal C vaccination of children aged less than 1 year (2003) (0)
ECONOMIC EVALUATION OF VACCINES (2012) (0)
A NEO-RICARDIAN APPROACH TOWARD DISCOUNTING (2010) (0)
Retrospective Public Health Impact of a Quadrivalent Influenza Vaccine in the United States Over the Period 2000-2014. (2014) (0)
PCV89 – Health Utilities Of Hypertensive Patients In Vietnam (2015) (0)
Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis (2023) (0)
University of Groningen Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination Gefenaite, (2013) (0)
Cost-effectiveness of increasing statin adherence for primary and secondary prevention in community pharmacies (2013) (0)
Cost analysis of screening testing for Covid-19 surveillance: A systematic review (2022) (0)
Deciding On Universal Rotavirus Vaccination In The Netherlands - Again (2017) (0)
Global Burden ofMultipleMyeloma ASystematicAnalysis for theGlobal BurdenofDisease Study 2016 (2018) (0)
Promotion of therapy adherence for COPD saves costs (2014) (0)
PIN5 DYNAMIC MODELLING FOR ESTIMATING THE COST-EFFECTIVENESS OF A CHLAMYDIA TRACHOMATIS SCREENING PROGRAM (2004) (0)
PCN187 BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS (2019) (0)
PIN32 THE POTENTIAL EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF A NEW COMBINATION VACCINE AGAINST MENINGOCOCCAL B AND C AND PNEUMOCOCCAL INFECTIONS IN THE NETHERLANDS (2003) (0)
Targets for Interventions To Optimize Pharmacotherapy in Asthma COPD Patients (2012) (0)
PDB34 A PERSONALIZED SCREENING STRATEGY FOR DIABETIC RETINOPATHY: A COST-EFFECTIVENESS PERSPECTIVE (2019) (0)
PNS11 Safety Challenges in the Procedures for Access and Affordability of Innovative Treatments (2020) (0)
Changes in HIV prevalence among men and women between the 2005-06 and 2010-11 Zimbabwe Demographic and Health Surveys (2014) (0)
OP39 The Real-Option Rate Of Return Approach To Inform The Pricing Of Medicines (2022) (0)
The Evaluation of Economic Methods to Assess the Social Value of Medical Interventions for Ultra-Rare Disorders (URDS). (2014) (0)
The dynamic field of pharmacoeconomics (2009) (0)
Book Reviews · Buchbesprechungen (2001) (0)
Health economics of technologies in blood transfusion within the context of general HTAs (2013) (0)
PMC9 A NEO-RICARDIAN APPROACH TOWARD DISCOUNTING (2010) (0)
[Rotavirus vaccination for all Dutch infants]. (2022) (0)
PRM122 - BOOTSTRAPPING PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL TO CAPTURE THEIR CORRELATION IN PROBABILISTIC SENSITIVITY ANALYSES (2018) (0)
PMU24 - WHICH MODEL(S) ARE USED TO ASSESS INDIVIDUAL-LEVEL SURROGACY IN ONCOLOGY USING KENDALL’S TAU? A SYSTEMATIC LITERATURE REVIEW (2018) (0)
PUK8 COST-EFFECTIVENESS OF SCREENING FOR ALBUMINURIA AND SUBSEQUENT TREATMENT WITH AN ACE-INHIBITOR; A PHARMACO-ECONOMIC ANALYSIS (2005) (0)
PRS14 Pharmacoeconomic Evaluations of Recent Chronic Obstructive Pulmonary Disease Pharmacotherapy: Systematic Review of Their Readiness for the Real-World (2020) (0)
PDG19 Budget and Health Impacts of Switching Atrial Fibrillation Patients to Dabigatran, Taking INR Control, Unique Dosing-Evidence and Product Lifecycle Outcomes Explicitly into Account (2020) (0)
PRS17 COST-EFFECTIVENESS OF A HYPOTHETICAL SCREENING PROGRAM FOR LUNG CANCER AND CARDIOVASCULAR DISEASE IN CHINA (2019) (0)
PCV57 A Systematic Literature Review of Cost-Utility Analyses of PCSK9 Inhibitors (2020) (0)
Drugprice Developments After Patent Expiry (2017) (0)
[Quantifying the impact of mass vaccination programmes on notified cases in the Netherlands]. (2018) (0)
Cost-Effectiveness of Additional Human Papillomavirus Vaccination Programmes, in The Netherlands (2017) (0)
Author's Reply. (2020) (0)
health effects in cost effectiveness analyses Need for differential discounting of costs and (2006) (0)
Modelling the health-care costs of drug-use-related disease: Part V: Economic Models, Chapter 12 (2001) (0)
PIN65 Systematic Literature Review on Modelling of Infectious Diseases in Elderly (2021) (0)
Cost-Effectiveness Analysis of Spending on Research and Development to Address the Needs for Innovative Therapeutic Products in Indonesia (2020) (0)
HS2 COST-EFFECTIVENESS OF LEUKODEPLETION IN MAJOR CARDIAC SURGERY (2002) (0)
Cost-effectiveness of vaccination for Haemophilus influenzae type b: A decision analysis in Cuba (2002) (0)
The impact of withdrawal rofecoxib on NSAIDs utilization (2010) (0)
Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs-Can Alignment Be Enhanced? (2022) (0)
Knowledge on hypertension in Myanmar: levels and groups at risk (2022) (0)
MO4 - COMPARING MIXTURE CURE MODELS WITH STANDARD PARAMETRIC MODELS WITHIN THREE- AND FIVE-STATE PARTITION SURVIVAL FRAMEWORKS (2018) (0)
PNS36 NOVEL Development and Pricing MODEL for Pharmaceutical Products (2020) (0)
PIN99 Modelling the Impact of Extended Vaccination Strategies on the Epidemiology of Pertussis (2011) (0)
PPA_A_339876 105..112 (2022) (0)
PIN10 COST-EFFECTIVENESS OF DIFFERENT PERTUSSIS VACCINATION STRATEGIES FORTHE PROTECTION OF YOUNG INFANTS (2007) (0)
COST EFFECTIVENESS OF CERVICAL CANCER SCREENING IN SERBIA (2011) (0)
PCN420 NEW METHODOLOGIES IN PARAMETRIC NETWORK META-ANALYSIS: ACCOUNTING FOR POPULATION AGE DIFFERENCES BETWEEN TRIALS (2019) (0)
University of Groningen Enhanced decision support for policy makers using a web interface to health-economic models - Illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands Hubben, (2007) (0)
Effects of the occurrence of a first cardiovascular event on statin adherence in type 2 diabetes: A matched cohort design (2013) (0)
Lifelong Apixaban Treatment Is Cost-Effective For The Prevention of Venous Thromboembolism In The Netherlands (2017) (0)
An Analysis of How Not to Use Cost-Effectiveness Analysis for Price-Setting (2013) (0)
Health Economic Evaluation Of Elective Cardioversion Of Atrial Fibrillation With Rivaroxaban Versus Vitamin K Oral Antagonists (2017) (0)
Cost-effectiveness of thrombus aspiration compared to conventional PCI in acute myocardial infarction: 1 year follow-up of the TAPAS-trial (2010) (0)
Baseline analysis HIV / AIDS in the Netherlands: 1982-1991 (1992) (0)
Applying systems thinking to identify enablers and challenges to scale-up interventions for hypertension and diabetes in low-income and middle-income countries: protocol for a longitudinal mixed-methods study (2022) (0)
PP83 A Conceptual Decision-Making Framework For Pharmaceutical Innovations (2019) (0)
Author’s response to reviews Title: Diabetes distress in Indonesian patients with type 2 diabetes: a comparison between primary and tertiary care Authors: (2019) (0)
Author’s response to reviews Title: Diabetes distress in Indonesian patients with type 2 diabetes: a comparison between primary and tertiary care Authors: (2019) (0)
Risk behaviour and the spread of HIV (1992) (0)
Deterministic Vs Microsimulation; A Case Study In Systemic Lupus Erythematosus (SLE) (2016) (0)
17th Biennial European Meeting of the Society for Medical Decision Making Leiden, the Netherlands, June 10–12, 2018 (2018) (0)
Reference scenario: Impact of AIDS in 1995 and 2000 (1992) (0)
PRM173 On the Probability of Intertemporal Indifference (2012) (0)
Costs of two vancomycin-resistant enterococci outbreaks in an academic hospital (2023) (0)
Pharmacoeconomic Analysis Of Dalbavancin Use In Acute Bacterial Skin And Soft Tissue Infections (2017) (0)
PHP55 RECOMMENDATIONS FOR ORPHAN DRUGS IN TWO EU MEMBER STATES—A FOCUS ON THE UNDERLYING PHARMACOECONOMIC EVALUATIONS (2009) (0)
PIN60 - ECONOMIC EVALUATION OF BCG VACCINATION : A SYSTEMATIC REVIEW AND QUALITY ASSESSMENT (2018) (0)
Cost-Effectiveness of Rivaroxaban Within Subgroups for Atrial Fibrillation and Venous Thromboembolism in The Netherlands (2016) (0)
University of Groningen Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands de Vries, Folgerdiena (2014) (0)
Evaluations of training and education interventions for improved infectious disease management in low-income and middle-income countries: a systematic literature review (2022) (0)
6. MF59 ASSURANCE 2: A Real-world Study to Estimate the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-based Trivalent High-dose Among U.S. Older Adults During 2018–19 Influenza Season (2020) (0)
PCN89 Estimating the costs of the management of non-HodgkinÂ’s lymphoma at a tertiaryÂ health institution (2021) (0)
PCN430 USING BAYESIAN METHODOLOGIES TO INFORM IMMATURE SURVIVAL EXTRAPOLATIONS BASED ON RWD AND EXPERT ELICITATION IN NON-SMALL CELL LUNG CANCER (NSCLC) (2019) (0)
[Continue to use the bivalent HPV vaccine; bivalent vaccine more effective than expected]. (2020) (0)
University of Groningen Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting beta(2)-agonists (2014) (0)
Healthy aging through lifelong vaccination: a tale of two countries (2013) (0)
PDB11 DRUG-USE PATTERNS OF INITIALLY PRESCRIBED INSULIN DETEMIR AND INSULIN GLARGINE IN THE NETHERLANDS;A COMPARATIVE ANALYSIS USING PHARMACY DATA FROM IADB. NL (2010) (0)
PRM255 - QUANTIFYING SYSTEMATIC ERROR IN UNANCHORED INDIRECT COMPARISONS: THE IN-SAMPLE METHOD (2018) (0)
Lesser medical cost of bleeding with COX-2-selective inhibitors compared with NSAIDs in concomitant coumarine users (2003) (0)
77 Economics and Vaccines (2010) (0)
TRANSMISSIBLE DISEASES AND BLOOD TRANSFUSION, PROCEEDINGS (2002) (0)
PCN242 Differences in Evidence Requirements in Oncology Drug Assessment between Health Technology Assessment (HTA) Bodies and EMA and HTA Bodies Among Themselves (2020) (0)
Albuminuria-dependent effect of blood pressure-lowering drugs in preventing cardiovascular events (2008) (0)
PIN52 A MODEL to Explore Clinical Outcomes with High Hepatitis B VIRUS Surface Antigen (HBSAG) Loss Rates in Chronic Hepatitis B (CHB) (2020) (0)
Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands (2023) (0)
Application effects around the expiration of patents for omeprazole and simvastatin: Generic substitution, no resubstitution (2004) (0)
PCN413 A BAYESIAN MIXTURE CURE MODEL USING INFORMATIVE PRIORS (2019) (0)
PCN66 - LANDMARK ANALYSES IN ONCOLOGY – SEEING BEYOND THE SURFACE AND PROPOSING A STRUCTURED DATA ANALYSIS CHECKLIST (2018) (0)
Direct medical costs of serious gastrointestinal ulcers attributable to non steroidal anti-inflammatory drugs in the Netherlands. (2006) (0)
Economic evaluation of dabigatran for the treatment and secondary prevention of venous thromboembolism (2015) (0)
Meta-analysis of quality of life in coronary heart disease (2013) (0)
RM2 - MIXTURE METHODS INCORPORATING GENERAL POPULATION MORTALITY IN THE LIKELIHOOD FUNCTION OF PARAMETRIC DISTRIBUTIONS (2018) (0)
DIFFERENTIAL TIME PREFERENCE FOR MONEY, LIFE YEARS AND QUALITY OF LIFE (2012) (0)
Improving somatic health of outpatients with severe mental illness (2014) (0)
CP1 THE IMPACT OF USING AGGREGATE DATA FOR MULTISTATE MODELLING PURPOSES IN ECONOMIC EVALUATIONS (2019) (0)
Table of Contents (2021) (0)
All PPIs equivalent for treatment of GERD. (2005) (0)
Introducing the encepp working group (WG) on health technology assessment (HTA): Enhancing the generation of additional evidence for HTA processes (2013) (0)
The impact of cardiovascular risk, baseline LDL-cholesterol, treatment dose and adherence on cost-effectiveness of statins in newly diagnosed diabetes patients (2015) (0)
PRS15 The Economic Impact of COPD in Patients of Working Age: Results From ‘COPD Uncovered' the Netherlands (2012) (0)
Moving Dietary Management of Diabetes Forward (2017) (0)
The Burden of Hyperglycemia First Detected in Pregnancy Among Indonesian Women (2020) (0)
Blood transfusion practices in obstetric care at a tertiary referral hospital in Zimbabwe (2015) (0)
HIV PREVALENCE IN FIRST-TIME AND REPEAT BLOOD DONATIONS IN ZIMBABWE, IMPACT ON BLOOD SAFETY (2012) (0)
Author Correction: Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017 (2020) (0)
The use of continuing use of drugs in relation to the risk for microalbuminuria and impaired renal funtion. (2007) (0)
Pharmaco-economics of blood products (2007) (0)
Indirect treatment comparison and economic evaluation of novel oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in the Netherlands (2013) (0)
Doelmatigheid van Humaan papillomavirus-vaccinatie--schattingen op basis van Nederlandse kosteneffectiviteitanalyses. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses] (2009) (0)
[Treatment with infliximab in patients with Crohn disease; experience in 132 patients]. (2002) (0)
Costs and Cost Effectiveness of School Health Systems (2018) (0)
Pharmacoeconomics 2007; 25 (6): 497-509 (2018) (0)
Immunogenicity and safety of human papillomavirus ( HPV ) vaccination in Asian populations from six countries (2017) (0)
Cost-effectiveness of leukoreduction in major cardiac surgery (2002) (0)
Turkish Aesthetic Surgeons’ Websites as Online Information Sources for Medical Tourism (2020) (0)
The use of Historical Trial Data to Inform Extrapolations of Immature Survival Data within a Bayesian Framework in Comparison to Standard Approaches (2018) (0)
PCN101 Cost Effectiveness of Everolimus for Second Line Treatment of Metastatic Renal Cell Cancer in Serbia (2012) (0)
PCV11 Indirect Treatment Comparison (ITC) of Novel Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients With Atrial Fibrillation (2012) (0)
14. A Comprehensive Real-World Analysis to Compare Adjuvanted Trivalent Influenza Vaccine and Trivalent High Dose Influenza Vaccine by Age and Period of High Influenza Activity for the 2018–19 Season among U.S. Elderly (2020) (0)
PCN268 Feasibility & IMPACT of Telemonitoring on Correct Drug Use, Monitoring on Adverse Events to Prevent Complications By Patients with Multiple Myeloma (MM). (F-ITUMM-TRIAL) (2020) (0)
Cost-Effectiveness of Rotavirus Vaccination in Hangzhou, China: A Comparison Between two Vaccines (2016) (0)
The Impacts of Deep Surgical Site Infections on Readmissions, Length of Stay, and Costs: A Matched Case–Control Study Conducted in an Academic Hospital in the Netherlands (2020) (0)
ECONOMIC EVALUATION OF DABIGATRAN FOR STROKE PREVENTION AMONG PATIENTS WITH ATRIAL FIBRILLATION IN THE NETHERLANDS (2012) (0)
The optimization of coumarin anticoagulant therapy: pharmacogenetics and computer assisted dose finding (2007) (0)
PRM141 - COMPARISON OF NOVEL BAYESIAN METHODS USING EXTERNAL DATA TO IMPROVE SURVIVAL ESTIMATIONS FROM IMMATURE SURVIVAL DATA (2018) (0)
Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy (2021) (0)
PCV102 COST-EFFECTIVENESS OF VARIOUS 'SCREEN-AND-TREAT' SCENARIOS DIRECTED AT ELEVATED ALBUMINURIA TO PREVENT CARDIOVASCULAR AND RENAL DISEASE IN THE GENERAL POPULATION (2009) (0)
PIN5: COST-UTILITY ANALYSIS OF A PNEUMOCOCCAL/MENINGOCOCCAL COMBINATION VACCINE FOR INFANTS (2001) (0)
PCN447 NEW METHODOLOGY IN PARAMETRIC NETWORK META-ANALYSIS: NON-MIXTURE CURE MODELS (2019) (0)
Cost utility analysis of everolimus in the treatment of metastatic renal cell cancer in the Netherlands (2013) (0)
Final report: Part 6 – Costs and Cost effectiveness of Interventions (2002) (0)
O2-S4.02 Cost-effectiveness of screening for Chlamydia trachomatis in Dutch pregnant women (2011) (0)
96. Relative Vaccine Effectiveness Against Influenza-Related and Any Respiratory-Related Hospital Encounter During the 2019/20 High Influenza Activity Period: A Comprehensive Real-World Analysis to Compare Quadrivalent Cell-based and Egg-based Influenza Vaccines (2021) (0)
Pharmacoeconomics 2004; 22 (18): 1171-1179 (2004) (0)
Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients. (2018) (0)
PMD18 INDIRECT COSTS OF A LARGE-SCALE IMMUNIZATION PROGRAM—WHEN COSTS EXCEED SAVINGS (2003) (0)
[Splenectomy and pneumococcal vaccination]. (2003) (0)
Network Meta-Analysis of Survival Data Using Fractional Polynomials - an Example with First Line Metastatic Renal cell cancer Treatments. (2015) (0)
Trends in Health Technology Assessments since the Introduction of Cost-Effectiveness in the Netherlands (2016) (0)
All proton pump inhibitors are equivalent for treatment of GERD (2005) (0)
PNS333 EXTRAPOLATING SURVIVAL BY ASSUMING PROPORTIONAL HAZARDS BETWEEN GENERAL POPULATION MORTALITY AND DISEASE SPECIFIC MORTALITY (2019) (0)
Cost-effectiveness of infant pneumococcal vaccination in the Netherlands (2013) (0)
PUK13 COST-EFFECTIVENESS OF INTRODUCING A DIETARY INTERVENTION FOR RENAL TRANSPLANT RECIPIENTS (2019) (0)
Value Of Information Analysis Using Generalized Additive Model Regression: A Case Study In Heart Failure Disease Management (2017) (0)
PIN35 HEALTH ECONOMIC ASSESSMENT OF A PRE-PANDEMIC INFLUENZA VACCINE FOR GERMANY (2008) (0)
Part 1: What is modelling and how can it be used? (2001) (0)
PIN35 MENINGOCOCCAL C VACCINATION OF CHILDREN AGED LESS THAN 1 YEAR: INCLUSION OF HERD IMMUNITY LEADS TO LESS FAVORABLE COST-EFFECTIVENESS RATIOS (2003) (0)
Encyclopedia of medical decision making (2009) (0)
Can overall survival be improved in elderly multiple myeloma patients (2015) (0)
PID3: COST-EFFECTIVENESS OF HEPATITIS B VACCINATION IN THE NETHERLANDS (2000) (0)
25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season (2021) (0)
Potential Savings Achieved Through Switching COPD Patients from ICS-Containing Regimens to LAMA-LABA: A Dutch Perspective (2017) (0)
Economic evaluation of vaccines: considerations on evidence, discounting, models and futures challenges (2012) (0)
An Update of Cost-Effectiveness of Rotavirus Vaccination in Indonesia: Taking a Birth-Dose Vaccination Strategy into Account. (2014) (0)
Cost and clinical outcomes in the use of new oral anticoagulants versus warfarin in deep vein thrombosis: A systematic review protocol (2022) (0)
PIH6 Cost-Effectiveness of Rotavirus Immunization in Vietnam: Exploring Impacts of Herd Immunity and Patterns of Breastfeedingof (2012) (0)
PUK15 THE COST-EFFECTIVENESS OF LANTHANUM CARBONATE IN THE TREATMENT OF HYPERPHOSPHATEMIA IN DIALYSIS PATIENTS FROM A CANADIAN PERSPECTIVE (2011) (0)
Mathematical Model to Synthesize Natural History of Tick Borne Encephalitis and Lyme Borreliosis for the Purpose of Cost-Effectiveness Analysis (2016) (0)
Assessing the economic burden and benefit-cost of treating attention-deficit hyperactivity disorder in Germany (2013) (0)
Evaluation of Interventions to Improve Somatic Health in Severe Mental Illness : A Conceptual Framework (2013) (0)
The application of multi-criteria decision analysis to inform in resource allocation [version 1; peer review: 1 approved, 1 approved with reservations] (2021) (0)
PCN409 BAYESIAN NETWORK META-ANALYSIS FOR MIXTURE CURE MODELS (2019) (0)
Effectiveness of the Influenza A(H1N1)pdm09 Vaccine in Adults Recommended for Annual Influenza Vaccination: A Case-Control Study (2012) (0)
PIN18 COST-EFFECTIVENESS ANALYSIS OF UNIVERSAL NEWBORN VACCINATION AGAINST HEPATITIS B VIRUS IN VIETNAM (2010) (0)
PRM80 - THE USE OF EXTERNAL DATA TO BETTER INFORM SURVIVAL EXTRAPOLATIONS IN SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) (2018) (0)
A Systematic Review Of The Cost-Effectiveness Of Quadrivalent Influenza Vaccine (2016) (0)
University of Groningen Investment decisions in influenza pandemic contingency planning (2009) (0)
Cost-effectiveness of angiotensin receptor blockers in patients with hypertension (2007) (0)
PRM243 - NETWORK META-ANALYSES ON SURVIVAL DATA: A COMPARISON AND GUIDANCE FOR DIFFERENT METHODOLOGIES (2018) (0)
PCN213 Health IMPACT of Optimizing the Time to Patient Access (2020) (0)
Cost-Effectiveness Analysis Of Invasive Fungal Infections Therapies In Febrile Neutropenic Patients With Hematological Malignancies In The Turkish Context (2017) (0)
The response to AIDS: strategies for AIDS control and care (1992) (0)
PRM138 - THE DIVE FRAMEWORK FOR USING DIFFERENT TYPES OF INFORMATION IN ESTIMATING LIFETIME CLINICALLY PLAUSIBLE EFFECTIVENESS (2018) (0)
PIN65 COST-EFFECTIVENESS ANALYSIS ON ELDERLY PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS: CHALLENGING THE DUTCH HEALTH COUNCIL'S ADVICE (2019) (0)
29. Impact of Enhanced Influenza Vaccines on Direct Healthcare Costs for the U.S. Elderly: A Comprehensive Real-World Evaluation of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine for the 2018–19 Influenza Season (2020) (0)
PRM71 Differential Time Preference for Money, Life Years and Quality of Life: An Empirical Pilot Study (2012) (0)
PRM241 - AN OUT-OF-SAMPLE METHOD TO QUANTIFY SYSTEMATIC ERROR IN UNANCHORED INDIRECT COMPARISONS (2018) (0)
PIN45 HOWTO IMPROVE THE EXTERNAL VALIDITY AND EXTEND THE EXPIRATION DATE OF ECONOMIC EVALUATIONS (2007) (0)
University of Groningen Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey (2016) (0)
Cost Price Calculation (1970) (0)
PHP259 - PHARMACOECONOMIC GUIDELINES RECOMMENDATION FOR TURKEY CONSIDERING REFERENCE COUNTRIES (2018) (0)
PRM43 A Systematic Review on the Application of Cardiovascular Risk Prediction Models in Pharmacoeconomics, With a Focus on Primary Prevention (2012) (0)
Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings (2022) (0)
803Direct Costs and Duration of Hospitalization of Patients Hospitalized with Community Acquired Pneumonia: a Nationwide Retrospective Claims Database Analysis (2014) (0)
PCN28 Relationship between Surrogate Endpoints and Overall Survival in Studies That Prohibited Crossover or Reported Balanced Post-Progression Treatments; Pooled Analysis in Advanced NSCLC Patients (2020) (0)
PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMEN (2018) (0)
University of Groningen Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening (2017) (0)
The effect of including indirect protection effects on the cost-effectiveness of prevention measures against infectious diseases (2006) (0)
P353 The economics of 4 grams once daily mesalazine dosing compared with 4 grams twice daily in active ulcerative colitis (2013) (0)
Swot analysis of the blood transfusion chain in a large teaching hospital in Uganda; An observational base line study (2008) (0)
University of Groningen Economic Evaluations of Pharmacogenetic and Genomic Screening Programs Vegter, (2010) (0)
Assessment of the costs and outcomes of antiretroviral therapy in adult outpatients at a tertiary hospital in Harare, Zimbabwe (2015) (0)
Cost analysis of nosocomial outbreaks in an academic hospital setting (2015) (0)
1202The incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit (2019) (0)
Need for enhanced glucose screening in pregnant women in Indonesia (2016) (0)
Baseline analysis of the economic impact of HIV / AIDS 1982–1991 (1992) (0)
Assessing the impact of infection prevention – an incremental cost-benefit analysis (2016) (0)
PHP108 - DETERMINANTS OF THE UPTAKE OF ROTAVIRUS AND PNEUMOCOCCAL CONJUGATE VACCINES IN ETHIOPIA (2018) (0)
Impact of digital interdisciplinary consultation on secondary care referrals by general practitioners: a protocol for a stepped-wedge cluster randomised controlled trial (2022) (0)
Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands (2021) (0)
Cost-effectiveness of targeted therapeutics in metastatic renal cell cancer seen from two different economic perspectives (2014) (0)
PRM236 - CALIBRATING MATCHING ADJUSTED INDIRECT COMPARISON ESTIMATE TO REAL-WORLD POPULATION (2018) (0)
PCV44 Cost-Effectiveness of a CYP2C19 Genotype-Guided Antiplatelet Strategy in ST-Segment Elevation Myocardial Infarction Patients: An Analysis Based on the Randomized Popular Genetics Trial (2020) (0)
Cost-effectiveness of diabetes screening in patients with psychotic disorders in a model and preliminary results of implementation of screening in psychiatric care (2011) (0)
Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe. (2023) (0)
Modelling drug use (2001) (0)
50 IS ADDING HCV SCREENING TO THE ANTENATAL NATIONAL SCREENING PROGRAM IN AMSTERDAM, THE NETHERLANDS COST-EFFECTIVE? (2013) (0)
Cost-effectiveness of Cyp2d6 genotyping in older depressed patients, starting with nortriptyline therapy (2015) (0)
Baseline Population Characteristics And The Association Between Progression-Free Survival And Overall Survival In Advanced Non-Small Cell Lung Cancer Patients (2017) (0)
PNS123 IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE IN INDONESIA (2019) (0)
1341. Relative Vaccine Effectiveness Against Influenza-related Hospitalizations and Respiratory Events During the 2019/20 Influenza seAson in U.S. Children and Adults. A Real-World Evidence Comparison Between Quadrivalent Cell-based and Egg-based Influenza Vaccines (2021) (0)
PCN393 - THE BURDEN OF INFORMAL CARE FOR BREAST CANCER PATIENTS IN THE NETHERLANDS (2018) (0)
PAR27 WITHDRAWAL OF ROFECOXIB FROMTHE MARKET; THERAPEUTIC AND ECONOMIC IMPLICATION FOR THE NETHERLANDS (2007) (0)
Pharmacoeconomics of Pharmacogenetics within the Context of General Health Technology Assessments (2013) (0)
Pharmo-economics of drug addiction (2002) (0)
University of Groningen Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands (2018) (0)
PIN31 COSTS AND EFFECTS OF CHLAMYDIAL SCREENING PROGRAMS: DYNAMIC VERSUS STATIC MODELING (2004) (0)
EPA-0301 – Improving Somatic Health of Outpatients With Severe Mental Illness (2014) (0)
The economic proﬁle of antenatal HIV testing: pharmaceutical and methodological considerations (2003) (0)
Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: the case of switching to High-Dose influenza vaccine for Dutch older adults. (2022) (0)
PSU7 THE DUTCH REFERENCE PRICE FOR INPATIENT DAYS SHOULD BE USED WITH SOME CAUTION (2019) (0)
Conceptual modeling framework for global functioning of ADHD patients (2017) (0)
Pharmocoeconomic aspects of losartan treatment to delay progression of renal disease inpatients with Type 2 diabetes (2003) (0)
University of Groningen Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data (2017) (0)
[Screening for Chlamydia trachomatis infection: which target group and at what price?]. (1999) (0)
Abstract 16390: Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients (2020) (0)
PIN114 UNDERSTANDING CHANGES IN FULL CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA BETWEEN 2000 AND 2016: OAXACA-BLINDER DECOMPOSITION ANALYSIS (2019) (0)
PIN25 LONG TERM EFFECT OF WARD PHARMACY CONTROLLED ADMINISTRATION OF ANTIBIOTICS ON ANTIMICROBIAL TREATMENT COSTS (2006) (0)
Chapter 3 An Economic Assessment of Losartan-Based Versus Atenolol-Based Therapy in Patients with Hypertension and Left-Ventricular Hypertrophy : Results From the Losartan Intervention For Endpoint reduction Study Adapted to The Netherlands (2009) (0)
PCN452 COMPARING OUTCOMES OF DIFFERENT STANDARD AND NOVEL APPROACHES THAT INCORPORATE GENERAL POPULATION MORTALITY HAZARDS IN SURVIVAL EXTRAPOLATIONS (2019) (0)
PCV99 COMPLIANCE AND PERSISTENCE WITH ANTIHYPERTENSIVES IN THE NETHERLANDS; A COMPARATIVE ANALYSIS WITH SPECIFIC FOCUS ON RAAS INTERVENING AGENTS (2010) (0)
PSY1 Matching-Adjusted Indirect Comparison of the Efficacy of Recombinant Factor VIII FC and Bay 94-9027 for the Treatment of Patients with Haemophilia a (2020) (0)
What Are Dynamic Models and How Can They Be Used (2001) (0)
Author response : economic evaluation of dabigatran etexilate. (2013) (0)
PCV154 THE INFLUENCE OF INSURANCE COMPANIES' REGULATIONS ON DRUG UTILIZATION; THE EXAMPLE OF SIMVASTATIN AND PREFERENCE POLICY (2009) (0)
METHODS FOR DISCOUNTING IN ECONOMIC EVALUATION; AN EMPIRICAL COMPARISON OF PREFERENCES IN MONEY AND QUALITY OF LIFE (2012) (0)
Modelling Lifetime Survival Gain In Patients With Transthyretin Amyloid Cardiomyopathy And Baseline NYHA III: An Analysis Of ATTR-ACT And Long Term Extension Study (2022) (0)
PIN68 THE COST-EFFECTIVENESS OF HEPATITIS C VIRUS SCREENING AND TREATMENT STRATEGIES AMONG RECENTLY ARRIVED MIGRANTS FOR THE NETHERLANDS (2019) (0)
PMH59 MODELLING THE ANTIDEPRESSANTS MARKET BEHAVIOUR AFTER PATENT EXPIRIES (2008) (0)
PCP23 - DOES THE EUROPEAN UNION (EU) NEED EUROPEAN HTA OR EUROPEAN PROCUREMENT? (2018) (0)
Author's reply: Solvent–detergent‐treated plasma: clinical evidence prior to economics (2003) (0)
PCV42 COST-EFFECTIVENESS OF POPULATION-BASED 'SCREEN-AND-TREAT' STRATEGIES DIRECTED AT ALBUMINURIA (2008) (0)
PCV9 Health IMPACT of Tafamidis in Transthyretin Amyloid Cardiomyopathy Patients: An Analysis from the Attr-ACT and the OPEN-Label Extension Studies (2020) (0)
AC1 PERSISTENCE WITH ANTIHYPERTENSIVE DRUG CLASSES; INFLUENCE OF METHOD ASSUMPTIONS (2009) (0)
Cost-effectiveness of statins for primary prevention in newly diagnosed type 2 diabetes patients: An illustration for The Netherlands (2013) (0)
PIN25 EXPLORATORY ANALYSIS OF THE ECONOMICALLY JUSTIFIABLE PRICE OF AN RSV VACCINE FOR THE ELDERLY IN THE NETHERLANDS AND THE UNITED KINGDOM (2019) (0)
COST-EFFECTIVENESS OF ROTAVIRUS IMMUNIZATION IN VIETNAM (2011) (0)
Part IV: Modelling the health consequences of drug use, Chapter 11: Developing multinational scenario analysis of health impacts of drug use (2001) (0)
PRM234 - HAZARD RATIO ESTIMATION USING DIFFERENT METHODS: AN IMPACT ASSESSMENT (2018) (0)
PRS5 Cost-Effectiveness of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) in the Netherlands (2020) (0)
Cost-effectiveness of expanded HIV screening of blood donations in Ghana (2004) (0)
PID4: COST-EFFECTIVENESS OF PARTNER PHARMACOTHERAPY IN SCREENING FOR CHLAMYDIA TRACHOMATIS (1999) (0)
Translation and Psychometric Analysis of the Indonesian Versions of the Lysholm and Tegner Scores for Patients With Anterior Cruciate Ligament Injuries (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Maarten Jacubos Postma?

Maarten Jacubos Postma is affiliated with the following schools:

Maarten Jacubos Postma's Academic­Influence.com Rankings

Maarten Jacubos Postma's Degrees

Why Is Maarten Jacubos Postma Influential?

Maarten Jacubos Postma's Published Works

Published Works

What Schools Are Affiliated With Maarten Jacubos Postma?

Maarten Jacubos Postma's AcademicInfluence.com Rankings